Table 11A.

Numbers of Adverse Effects in Each Treatment Group Before/After Week 8

	Through week 8: Zinc monotherapy			After Week 8: with amphetamine
	Group			Group
Adverse effects	Placebo	Zinc_1	Zinc_2	Placebo	Zinc_1	Zinc_2
Affective blunting	1 (4.17%)	1 (5%)	0 (0%)	6 (25%)	4 (20%)	0 (0%)
Anxiety	6 (25%)	6 (30%)	2 (25%)	5 (20.83%)	9 (45%)	3 (37.5%)
Appetite	4 (16.7%)	3 (15%)	4 (50%)	17 (70.8%)	15 (75%)	8 (100%)
Cardiovascular	0 (0%)	0 (0%)	0 (0%)	2 (8.33%)	0 (0%)	0 (0%)
Central nervous system reactions	0 (0%)	0 (0%)	1 (12.5%)	7 (29.17%)	1 (5%)	0 (0%)
Dental	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (10%)	1 (12.5%)
Depression	5 (20.8%)	7 (35%)	2 (25%)	9 (37.5%)	11 (55%)	4 (50%)
Fatigue	6 (25%)	2 (10%)	2 (25%)	2 (8.33%)	5 (25%)	5 (62.5%)
Fever	0 (0%)	2 (10%)	1 (12.5%)	1 (4.17%)	2 (10%)	1 (12.5%)
Harm to self and others	0 (0%)	1 (5%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)
Head, eyes, ears, nose, and throat	3 (12.5%)	3 (15%)	1 (12.5%)	2 (8.33%)	4 (20%)	1 (12.5%)
Headache	13 (54.2%)	5 (25%)	2 (25%)	8 (33.3%)	8 (40%)	3 (37.5%)
Hypersensitivity reaction	1 (4.17%)	3 (15%)	0 (0%)	5 (20.8%)	0 (0%)	1 (12.5%)
Irritability	10 (41.7%)	9 (45%)	5 (62.5%)	14 (58.3%)	9 (45%)	6 (75%)
Musculoskeletal	4 (16.7%)	1 (5%)	0 (0%)	2 (8.33%)	1 (5%)	0 (0%)
Other	2 (8.33%)	0 (0%)	0 (0%)	2 (8.33%)	0 (0%)	0 (0%)
Respiratory	5 (20.8%)	8 (40%)	0 (0%)	4 (16.7%)	5 (25%)	0 (0%)
Slapped in Face	1 (4.17%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
School performance	0 (0%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Skin	3 (12.5%)	1 (5%)	1 (12.5%)	2 (8.33%)	2 (10%)	2 (25%)
Sleep	4 (16.7%)	0 (0%)	1 (12.5%)	16 (66.7%)	8 (40%)	6 (75%)
Stereotypical behaviors	5 (20.8%)	3 (15%)	1 (12.5%)	9 (37.5%)	7 (35%)	2 (25%)
Stomach aches	13 (54.2%)	6 (30%)	3 (37.5%)	11 (45.8%)	7 (35%)	3 (37.5%)
Other gastrointestinal	5 (20.8%)	5 (25%)	1 (12.5%)	3 (12.5%)	4 (20%)	0 (0%)
URI	4 (16.7%)	2 (10%)	0 (0%)	2 (8.33%)	1 (5%)	0 (0%)
Total number of AEs	95	69	27	129	106	46
Number of AEs/participant	3.96	3.45	3.38	5.38	5.3	5.75

AEs = adverse events; URI = upper respiratory infection.